The study concluded that sublingual sufentanil tablets provide the opportunity to non-invasively and rapidly treat moderate-to-severe pain in a monitored setting. Following dosing of the 30 mcg ...

The pooled analysis (N=804) evaluated clinical studies of sufentanil sublingual tablet (SST) at 30mcg dose equivalents over ≤72 hours for moderate-to-severe acute pain management in both ...

AcelRx Pharmaceuticals announced top-line results demonstrating that the first of two pivotal placebo-controlled Phase 3 studies for its investigational sublingual Sufentanil NanoTab PCA (patient ...

AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain -In this open-label study ...

About DSUVIA (sufentanil sublingual tablet), 30 mcg DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals ...

Investigators analyzed data from 50 patients who received sufentanil sublingual tablets (SSTs) postoperatively versus a control group of 21 patients who were treated according to standard pain ...

AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA ...